Market Place
Sourcing Support
Texas A&M Health and BurstIQ Partner to Revolutionize Clinical Genomics Research
17 Jul 2024 //
PR NEWSWIRE
Biotheryx Announces FDA Clearance of NDA for BTX-9341 Dual Bifunctional Degrader
07 May 2024 //
PR NEWSWIRE
Biotheryx to Present New Preclinical Data on Bifunctional Degraders
25 May 2023 //
PR NEWSWIRE
Biotheryx Presents Preclinical CDK4/6 & SOS1 Protein Degrader Data at AACR 2023
17 Apr 2023 //
PR NEWSWIRE
Incyte taps Biotheryx for $360M molecular glue degrader deal
06 Apr 2023 //
FIERCE BIOTECH
Biotheryx to Participate in Wells Fargo 2023 Targeted Protein Degradation Summit
15 Feb 2023 //
PR NEWSWIRE
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
24 Aug 2022 //
PRNEWSWIRE
Biotheryx Announces Appointment of Jeff Caravella as Chief Financial Officer
25 Apr 2022 //
PRNEWSWIRE
BioTheryX Begins Dosing in Phase 1 Study for BTX-1188
26 Jan 2022 //
PRNEWSWIRE
BioTheryX Receives IND Clearance FDA to Proceed with Phase 1 Study of BTX-1188
02 Nov 2021 //
PRNEWSWIRE
BioTheryX Announces First Patient Dosed with BTX-A51 in Phase 1 Clinical Trial
09 Jun 2021 //
PRNEWSWIRE
BioTheryX Announces Expansion of Scientific Advisory Board with Appointment
17 May 2021 //
PRNEWSWIRE
BioTheryX to Participate in Upcoming Scientific and Investor Events
15 Feb 2021 //
PRNEWSWIRE
BioTheryX Announces $35 Million Series D Financing
28 Jul 2020 //
PRNEWSWIRE
AbbVie backs an Italian startup focused on autoimmune diseases; BioTheryX
28 Jul 2020 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.